A growing body of translational research suggests that IN delivery can achieve CNS therapeutic effects while minimizing systemic exposure, allowing patients to experience fewer adverse effects, such as anemia or gastrointestinal upset, which are common concerns with oral or intravenous chelators
J Expo Sci Environ Epidemiol 35:632643
None is intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition.
This protocol uses lower doses to minimize side effects while establishing tolerance, making it ideal for individuals sensitive to appetite suppressants or those starting weight loss treatment for the first time
Its personalized formulation ensures it meets individual needs, while also supporting improved blood sugar regulation
FDA-approved for reducing visceral fat